The University of Southampton
University of Southampton Institutional Repository

Clinicopathological features and therapeutic outcomes of bladder cancer in younger adults

Clinicopathological features and therapeutic outcomes of bladder cancer in younger adults
Clinicopathological features and therapeutic outcomes of bladder cancer in younger adults
Objectives: to evaluate the clinicopathological features, recurrence and survival in patients up to 50 years of age diagnosed with primary bladder-cancer.

Methods: during a 14-year period (1997-2011), 71 patients aged ≤50 years with bladder-cancer were analyzed in a single institution. Survival probabilities and associations were calculated using Kaplan-Meier, log-rank and Chi-squared-tests.

Results: median age at diagnosis was 43.4 years (inter quartile-range [IQR] 39-47); median follow-up was 60.9 months (2.1-168.3). Non-muscle-invasive (NMI; pTa-pT1) bladder-cancer was commoner than muscle-invasive (MI; pT2-pT4) bladder-cancer (89% [n=63] versus 11% [n=8], respectively). Nineteen patients (27%) were ≤40 years and 52 (73%) were 41-50 years. MI bladder-cancer was commoner in 41-50-year group (13% [n=7/52]) than ≤40-year group (5% [n=1/19]; p=0.03), as was high-grade disease (23% [n=12/52] versus 16% [n=3/19], respectively; p=0.04). Twenty-one patients (30%) developed recurrence (29% [n=6/21] ≤40-years versus 72% [n=15/21] 41-50-years; p=0.12), with progression occurring only in 41-50-year group (19% [n=4/21]). A higher proportion of patients underwent cystectomy in the 41-50-year group (89% [n=8/9]) compared to those in the ≤40-year group (11% [n=1/9]; p=0.03). Five-year overall survival and cancer-specific survival were both 100% in ≤40-year group, and 84% and 86% in 41-50-year group, respectively. Among patients aged 41-50 years, those with MI bladder-cancer had particularly lower survival rates.

Conclusion: bladder-cancer in younger adults is generally characterized by less aggressive disease with a favorable outcome. However, there is an increase in tumors incidence, muscle invasion, recurrence and progression after 40 years of age. Higher cystectomy and lower survival rates are also observed in this age group.
Albayati, Mostafa A.
19b399e3-4132-4d1e-8478-fa489cfbce59
Pandian, Sivakumar S.
316ab825-9a50-4082-8f0e-2cc2c1eea54f
El Wilid, Bashir
e7c59131-82ad-4a14-a227-7370e91e3f21
Birch, Brian R.
536ee8d2-9cf9-4412-a29b-d2267fa9d765
Albayati, Mostafa A.
19b399e3-4132-4d1e-8478-fa489cfbce59
Pandian, Sivakumar S.
316ab825-9a50-4082-8f0e-2cc2c1eea54f
El Wilid, Bashir
e7c59131-82ad-4a14-a227-7370e91e3f21
Birch, Brian R.
536ee8d2-9cf9-4412-a29b-d2267fa9d765

Albayati, Mostafa A., Pandian, Sivakumar S., El Wilid, Bashir and Birch, Brian R. (2016) Clinicopathological features and therapeutic outcomes of bladder cancer in younger adults. Journal of Urology and Renal Diseases.

Record type: Article

Abstract

Objectives: to evaluate the clinicopathological features, recurrence and survival in patients up to 50 years of age diagnosed with primary bladder-cancer.

Methods: during a 14-year period (1997-2011), 71 patients aged ≤50 years with bladder-cancer were analyzed in a single institution. Survival probabilities and associations were calculated using Kaplan-Meier, log-rank and Chi-squared-tests.

Results: median age at diagnosis was 43.4 years (inter quartile-range [IQR] 39-47); median follow-up was 60.9 months (2.1-168.3). Non-muscle-invasive (NMI; pTa-pT1) bladder-cancer was commoner than muscle-invasive (MI; pT2-pT4) bladder-cancer (89% [n=63] versus 11% [n=8], respectively). Nineteen patients (27%) were ≤40 years and 52 (73%) were 41-50 years. MI bladder-cancer was commoner in 41-50-year group (13% [n=7/52]) than ≤40-year group (5% [n=1/19]; p=0.03), as was high-grade disease (23% [n=12/52] versus 16% [n=3/19], respectively; p=0.04). Twenty-one patients (30%) developed recurrence (29% [n=6/21] ≤40-years versus 72% [n=15/21] 41-50-years; p=0.12), with progression occurring only in 41-50-year group (19% [n=4/21]). A higher proportion of patients underwent cystectomy in the 41-50-year group (89% [n=8/9]) compared to those in the ≤40-year group (11% [n=1/9]; p=0.03). Five-year overall survival and cancer-specific survival were both 100% in ≤40-year group, and 84% and 86% in 41-50-year group, respectively. Among patients aged 41-50 years, those with MI bladder-cancer had particularly lower survival rates.

Conclusion: bladder-cancer in younger adults is generally characterized by less aggressive disease with a favorable outcome. However, there is an increase in tumors incidence, muscle invasion, recurrence and progression after 40 years of age. Higher cystectomy and lower survival rates are also observed in this age group.

Text
Clinicopathological Features and Therapeutic Outcomes of Bladder Cancer in Younger Adults - Accepted Manuscript
Download (110kB)
Text
Clinicopathological Features Table 1 - Accepted Manuscript
Download (51kB)
Image
Clinicopathological Features Figure 2 - Accepted Manuscript
Download (108kB)
Text
Clinicopathological features and therapeutic outcomes of bladder cancer in younger adults - Version of Record
Download (585kB)
Image
Clinicopathological Features Figure 1
Download (91kB)
Image
Clinicopathological Features Figure 3
Download (101kB)

Show all 6 downloads.

More information

Accepted/In Press date: 8 December 2016
Published date: 15 December 2016

Identifiers

Local EPrints ID: 412519
URI: http://eprints.soton.ac.uk/id/eprint/412519
PURE UUID: 9c6f79b8-7b37-49cb-a871-f680acdf0964

Catalogue record

Date deposited: 17 Jul 2017 14:04
Last modified: 15 Mar 2024 12:24

Export record

Contributors

Author: Mostafa A. Albayati
Author: Sivakumar S. Pandian
Author: Bashir El Wilid
Author: Brian R. Birch

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×